Study details
Enrolling now
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Hackensack Meridian Health
NCT IDNCT06798558ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
54
Study length
about 4.1 years
Ages
18+
Sex
Male only
Locations
3 sites in DC, NJ
What this study is about
This trial is testing a treatment called Lu-177-PSMA-617 for men with high risk localized prostate cancer who are scheduled to have surgery. The goal is to determine if this treatment can help improve outcomes in these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lu-17-PSMA-617
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Quality-of-life and sexual function changes